Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors.
Gabriela M Almeidai3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0001-8712-7394
Carla Pereirai3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0001-5892-0764
Ji-Hyeon ParkDepartment of Surgery, Seoul National University Hospital, Seoul 03080, Korea.ORCID 0000-0002-6811-8895
Carolina Lemosi3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0001-9803-9584
Sofia Campelosi3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0002-6847-5630
Irene Gulloi3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0003-3377-0530
Diana Martinsi3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0002-1457-8992
Gilza GonçalvesIpatimup-Institute of Molecular Pathology and Immunology of the University of Porto, 4200-135 Porto, Portugal.
Dina LeitãoFaculty of Medicine, University of Porto, 4200-319 Porto, Portugal.
João Luís NetoInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal.ORCID 0000-0003-0863-158X
Ana Andréi3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0002-0638-8304
Clara BorgesMedical Oncology Department, Centro Hospitalar Universitário de São João, 4200-319 Porto, Portugal.
Daniela AlmeidaMedical Oncology Department, Centro Hospitalar Universitário de São João, 4200-319 Porto, Portugal.ORCID 0000-0002-8373-3917
Hyuk-Joon LeeDepartment of Surgery, Seoul National University Hospital, Seoul 03080, Korea.ORCID 0000-0002-9530-647X
Seong-Ho KongDepartment of Surgery, Seoul National University Hospital, Seoul 03080, Korea.
Woo Ho KimDepartment of Pathology, Seoul National University College of Medicine, Seoul 03080, Korea.ORCID 0000-0003-0557-1016
Fátima Carneiroi3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0002-1964-1006
Raquel Almeidai3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0002-5622-1633
Han-Kwang YangDepartment of Surgery, Seoul National University Hospital, Seoul 03080, Korea.
Carla Oliveirai3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0001-8340-2264
Funding
ERDF funds through the COMPETE 2020 - POCI, Portugal 2020 and by FCT PTDC/BTM-TEC/30164/2017ERDF, POCI and FCT POCI-01-0145-FEDER-016390 and SAICTPAC/0022/2015FEDER-Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020-Operacional Programme for Competitiveness and Internationalization (POCI), Portugal 2020, and by Portuguese funds through FCT-Fundação para a Ciência e a Tecnologia/Ministério POCI-01-0145-FEDER-007274Fundação para a Ciência e a Tecnologia (FCT) (PTDC/CTM-NAN/120958/2010Fundação para a Ciência e a Tecnologia (FCT) SFRH/BD/113031/2015Norte Portugal Regional Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF) NORTE-01-0145-FEDER-000003Norte Portugal Regional Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF) NORTE-01-0145-FEDER-000029PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF) POCI-01-0145-FEDER-016390 and SAICTPAC/0022/2015
6 · The paper itself
Abstract
In gastric cancer (GC), biomarkers that define prognosis and predict treatment response remain scarce. We hypothesized that the extent of CD44v6 membranous tumor expression could predict prognosis and therapy response in GC patients. Two GC surgical cohorts, from Portugal and South Korea (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
CD44v6 High Membranous Expression Is a Predictive Marker of Therapy Response in Gastric Cancer Patients. · full record | OpenQuestion